The bank sees 2011 EPS of $2.04, down from $2.09 per share.
Edwards Lifesciences has a potential upside of 19.9% based on a current price of $78.7 and an average consensus analyst price target of $94.33.
Morgan Stanley lowered its 2011 EPS estimate for Edwards Lifesciences (NYSE:EW) and maintained its equal-weight rating on the stock.
